FIGURE 3.

Total tau (T‐tau) in the cerebrospinal fluid (CSF) in patients with inflammatory polyneuropathies and controls. (a) Absolute concentration of T‐tau in CSF. (b) Log transformed NfL values in GBS, Guillain–Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), paraproteinaemic demyelinating neuropathy (PDN), and multifocal motor neuropathy (MMN) vs. controls. (c) Log transformed NfL values in GBS and CIDP patients prior to and following immunomodulatory treatment. ALS, amyotrophic lateral sclerosis; CIDP, chronic inflammatory demyelinating polyneuropathy; GBS, Guillain–Barré syndrome; HA, headaches; HC, healthy controls; MMN, multifocal motor neuropathy; NIP, non‐inflammatory polyneuropathy; PDN, paraproteinaemic demyelinating neuropathy. a, pre‐treatment; b, post‐treatment; horizontal lines represent median values. ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001